Please login to the form below

Not currently logged in
Email:
Password:

CC-486

This page shows the latest CC-486 news and features for those working in and with pharma, biotech and healthcare.

BMS’ oral maintenance therapy boosts survival in AML patients

BMS’ oral maintenance therapy boosts survival in AML patients

We now look forward to taking the next steps to bring CC-486 to eligible AML patients in need,” he added. ... According to a statement issued by BMS, regulatory submissions for CC-486 are planned for the first half of 2020.

Latest news

  • Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial

    The formulation – known as CC-486 – is an orally-active version of Vidaza, Celgene’s already-marketed azacitidine product which is administered intravenously. ... The new  QUAZAR AML-001 study compared CC-486 to placebo as a maintenance therapy

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics